NHP · National Healthcare Properties, Inc.
Price & Indicators
The closing range uses available history since Apr 22, 2026; less than a full year is stored.
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
REIT - Healthcare Facilities — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
NHP
this stock
National Healthcare Properties, Inc.
|
$1.15B | — | -3.3% | — | 4.8% |
|
WELL
Welltower Inc.
|
$166.33B | +26.9% | +35.6% | 117.2 | 2.6% |
|
VTR
Ventas, Inc.
|
$46.16B | +16.3% | +18.5% | 166.7 | 4.0% |
|
OHI
Omega Healthcare Investors Inc
|
$14.24B | +6.0% | +13.2% | 16.7 | 4.3% |
|
DOC
Healthpeak Properties, Inc.
|
$14.00B | +26.2% | +4.5% | 58.0 | 3.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| NHP | -1.6% | -3.5% | — | -2.0% | — |
| SPY | -1.2% | -1.8% | +17.8% | -0.4% | +12.1% |
| vs SPY | -0.4% | -1.7% | — | -1.6% | — |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.